tetano
Editor, Senior Moderator
Cell Rep
. 2021 Aug 10;109604.
doi: 10.1016/j.celrep.2021.109604. Online ahead of print.
Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals
Elaine C Chen[SUP] 1 [/SUP], Pavlo Gilchuk[SUP] 2 [/SUP], Seth J Zost[SUP] 2 [/SUP], Naveenchandra Suryadevara[SUP] 2 [/SUP], Emma S Winkler[SUP] 3 [/SUP], Carly R Cabel[SUP] 4 [/SUP], Elad Binshtein[SUP] 2 [/SUP], Rita E Chen[SUP] 3 [/SUP], Rachel E Sutton[SUP] 2 [/SUP], Jessica Rodriguez[SUP] 2 [/SUP], Samuel Day[SUP] 2 [/SUP], Luke Myers[SUP] 2 [/SUP], Andrew Trivette[SUP] 2 [/SUP], Jazmean K Williams[SUP] 5 [/SUP], Edgar Davidson[SUP] 5 [/SUP], Shuaizhi Li[SUP] 6 [/SUP], Benjamin J Doranz[SUP] 5 [/SUP], Samuel K Campos[SUP] 7 [/SUP], Robert H Carnahan[SUP] 2 [/SUP], Curtis A Thorne[SUP] 4 [/SUP], Michael S Diamond[SUP] 8 [/SUP], James E Crowe Jr[SUP] 9 [/SUP]
Affiliations
Abstract
Unrelated individuals can produce genetically similar clones of antibodies, known as public clonotypes, which have been seen in responses to different infectious diseases, as well as healthy individuals. Here we identify 37 public clonotypes in memory B cells from convalescent survivors of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or in plasmablasts from an individual after vaccination with mRNA-encoded spike protein. We identify 29 public clonotypes, including clones recognizing the receptor-binding domain (RBD) in the spike protein S1 subunit (including a neutralizing, angiotensin-converting enzyme 2 [ACE2]-blocking clone that protects in vivo) and others recognizing non-RBD epitopes that bind the S2 domain. Germline-revertant forms of some public clonotypes bind efficiently to spike protein, suggesting these common germline-encoded antibodies are preconfigured for avid recognition. Identification of large numbers of public clonotypes provides insight into the molecular basis of efficacy of SARS-CoV-2 vaccines and sheds light on the immune pressures driving the selection of common viral escape mutants.
Keywords: COVID-19; SARS-CoV; SARS-CoV-2; adaptive immunity; antibodies; coronavirus; human; monoclonal; public clonotypes; vaccines.
. 2021 Aug 10;109604.
doi: 10.1016/j.celrep.2021.109604. Online ahead of print.
Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals
Elaine C Chen[SUP] 1 [/SUP], Pavlo Gilchuk[SUP] 2 [/SUP], Seth J Zost[SUP] 2 [/SUP], Naveenchandra Suryadevara[SUP] 2 [/SUP], Emma S Winkler[SUP] 3 [/SUP], Carly R Cabel[SUP] 4 [/SUP], Elad Binshtein[SUP] 2 [/SUP], Rita E Chen[SUP] 3 [/SUP], Rachel E Sutton[SUP] 2 [/SUP], Jessica Rodriguez[SUP] 2 [/SUP], Samuel Day[SUP] 2 [/SUP], Luke Myers[SUP] 2 [/SUP], Andrew Trivette[SUP] 2 [/SUP], Jazmean K Williams[SUP] 5 [/SUP], Edgar Davidson[SUP] 5 [/SUP], Shuaizhi Li[SUP] 6 [/SUP], Benjamin J Doranz[SUP] 5 [/SUP], Samuel K Campos[SUP] 7 [/SUP], Robert H Carnahan[SUP] 2 [/SUP], Curtis A Thorne[SUP] 4 [/SUP], Michael S Diamond[SUP] 8 [/SUP], James E Crowe Jr[SUP] 9 [/SUP]
Affiliations
- PMID: 34411541
- DOI: 10.1016/j.celrep.2021.109604
Abstract
Unrelated individuals can produce genetically similar clones of antibodies, known as public clonotypes, which have been seen in responses to different infectious diseases, as well as healthy individuals. Here we identify 37 public clonotypes in memory B cells from convalescent survivors of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or in plasmablasts from an individual after vaccination with mRNA-encoded spike protein. We identify 29 public clonotypes, including clones recognizing the receptor-binding domain (RBD) in the spike protein S1 subunit (including a neutralizing, angiotensin-converting enzyme 2 [ACE2]-blocking clone that protects in vivo) and others recognizing non-RBD epitopes that bind the S2 domain. Germline-revertant forms of some public clonotypes bind efficiently to spike protein, suggesting these common germline-encoded antibodies are preconfigured for avid recognition. Identification of large numbers of public clonotypes provides insight into the molecular basis of efficacy of SARS-CoV-2 vaccines and sheds light on the immune pressures driving the selection of common viral escape mutants.
Keywords: COVID-19; SARS-CoV; SARS-CoV-2; adaptive immunity; antibodies; coronavirus; human; monoclonal; public clonotypes; vaccines.